Treatment with Tafamidis in patients with transthyretin amyloid cardiomyopathy

被引：0

作者：

Rettl, R. ^{[1
]}

Christopher, M. ^{[1
]}

Dachs, T. ^{[1
]}

Duca, F. ^{[1
]}

Binder, C. ^{[1
]}

Dusik, F. ^{[1
]}

Seirer, B. ^{[1
]}

Eslam, R. Badr ^{[1
]}

Hengstenberg, C. ^{[1
]}

Bonderman, D. ^{[1
]}

机构：

[1] Med Univ Wien, Vienna, Austria

来源：

WIENER KLINISCHE WOCHENSCHRIFT | 2020年 / 132卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PS 26/26-6

引用

页码：S306 / S307

页数：2

共 50 条

[21] Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy [J].

Tian, Zhuang ;

Peng, Daoquan ;

Ma, Wei ;

Yan, Jiangtao ;

Wang, Jian'an ;

Tang, Yida ;

Jin, Wei ;

Liu, Ying ;

Jia, Caiping ;

Gao, Yingxu ;

Gong, Yankun ;

Sun, Xiaohong ;

Chen, Naihan ;

Zhu, Shuiqing ;

Zhang, Shuyang .

CARDIOLOGY AND THERAPY, 2025, 14 (03) :439-452

[22] Mortality Among Older Transthyretin Amyloid Cardiomyopathy Patients On Tafamidis [J].

Batra, Supria ;

Patel, Hina ;

Govi, Ashley ;

Panjrath, Gurusher .

JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)

[23] Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy [J].

Psotka, Mitchell A. .

JACC-HEART FAILURE, 2021, 9 (02) :124-126

[24] Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy [J].

Abramowicz, Mark ;

Zuccotti, Gianna ;

Pflomm, Jean-Marie .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05) :505-505

[25] Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis [J].

Wang, Jie ;

Chen, Hongyu ;

Tang, Zihuan ;

Zhang, Jinquan ;

Xu, Yuanwei ;

Wan, Ke ;

Hussain, Kifah ;

Gkoutos, Georgios, V ;

Han, Yuchi ;

Chen, Yucheng .

ECLINICALMEDICINE, 2023, 63

[26] DISEASE STABILIZATION IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY DURING THE FIRST YEAR OF TAFAMIDIS TREATMENT [J].

Pavia, Pablo Garcia ;

Witteles, Ronald ;

Hanna, Mazen A. ;

Damy, Thibaud ;

Angeli, Franca S. ;

Marino, Valentina ;

Wang, Rong ;

Crespo-Leiro, Maria G. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (12) :1338-1338

[27] Tafamidis (Vyndagel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy [J].

不详 .

MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1590) :16-16

[28] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy [J].

Rettl, R. ;

Wollenweber, T. ;

Mann, C. ;

Duca, F. ;

Dachs, T. ;

Binder, C. ;

Stojanovic, M. ;

Ligios, L. Camuz ;

Schrutka, L. ;

Dalos, D. ;

Charwat-Resl, S. ;

Hengstenberg, C. ;

Eslam, R. Badr ;

Kastner, J. ;

Hacker, M. ;

Bonderman, D. .

WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 3) :S105-S106

[29] Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy [J].

Badr Eslam, Roza ;

Ozturk, Begum ;

Rettl, Rene ;

Capelle, Christophe Denis Josef ;

Qin, Hong ;

Binder, Christina ;

Dachs, Theresa-Marie ;

Camuz Ligios, Luciana ;

Duca, Franz ;

Dalos, Daniel ;

Schrutka, Lore ;

Alasti, Farideh ;

Kastner, Johannes ;

Vila, Greisa ;

Bonderman, Diana .

CIRCULATION-HEART FAILURE, 2022, 15 (07)

[30] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy [J].

Rettl, R. Rene ;